Are gait and mobility measures responsive to change following botulinum toxin injections in adults with lower limb spasticity?

References

• Gracies JM, Marosszeky JE, Renton R, Sandanam J, Gandevia SC, Burke D. Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil 2000;81:1547–1555.
   PubMed Web of Science ®Google Scholar
• Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med 2006;38:166–171.
   PubMed Web of Science ®Google Scholar
• Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatr 1995;58:232–235.
   PubMed Web of Science ®Google Scholar
• Ozcakir S, Sivrioglu K. Botulinum toxin in poststroke spasticity. Clin Med Res 2007;5:132–138.
   PubMedGoogle Scholar
• Gracies JM, Singer BJ, Dunne JW. The role of botulinum toxin injections in the management of muscle overactivity of the lower limb. Disabil Rehabil 2007;29:1789–1805.
   PubMed Web of Science ®Google Scholar
• Richardson D, Sheean G, Werring D, Desai M, Edwards S, Greenwood R, Thompson A. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatr 2000;69:499–506.
   PubMed Web of Science ®Google Scholar
• Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, Mazaux JM, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatr 1996;61:265–269.
   PubMed Web of Science ®Google Scholar
• Dengler R, Neyer U, Wohlfarth K, Bettig U, Janzik HH. Local botulinum toxin in the treatment of spastic drop foot. J Neurol 1992;239:375–378.
   PubMed Web of Science ®Google Scholar
• Rousseaux M, Compère S, Launay MJ, Kozlowski O. Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles. J Neurol Sci 2005;232:51–57.
   PubMed Web of Science ®Google Scholar
• Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26:26–31.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Moore AP, Hardiman O, Ehler E, Kovac M, Bojakowski J, Al Khawaja I, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289–300.
   PubMed Web of Science ®Google Scholar
• Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998;79:532–535.
   PubMed Web of Science ®Google Scholar
• Hesse S, Luecke D, Jahnke MT, Mauritz KH. Gait function in spastic hemiparetic patients walking barefoot, with firm shoes, and with ankle-foot orthosis. Int J Rehabil Res 1996;19:133–141.
   PubMed Web of Science ®Google Scholar
• Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Müller J, Poewe W. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of “high-dose” versus “low-dose” treatment. Neuropediatrics 1999;30:120–124.
   PubMed Web of Science ®Google Scholar
• Ward AB. The use of botulinum toxin type A in spastic diplegia due to cerebral palsy. Eur J Neurol 1999;6(Suppl 4):S95–S98.
   Google Scholar
• Al-Khodairy AT, Gobelet C, Rossier AB. Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients? Spinal Cord 1998;36:854–858.
   PubMed Web of Science ®Google Scholar
• Fried GW, Fried KM. Spinal cord injury and use of botulinum toxin in reducing spasticity. Phys Med Rehabil Clin N Am 2003;14:901–910.
   PubMedGoogle Scholar
• Fock J, Galea MP, Stillman BC, Rawicki B, Clark M. Functional outcome following botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury. Brain Inj 2004;18:57–63.
   PubMed Web of Science ®Google Scholar
• Guo F, Yue W, Ren L, Zhang YM, Yang J. Botulinum Toxin type A plus rehabilitative training for improving the motor function of the upper limbs and activities of daily life in patients with stroke and brain injury. Neural Regen Res 2006;1:859–861.
   Google Scholar
• van Rhijn J, Molenaers G, Ceulemans B. Botulinum toxin type A in the treatment of children and adolescents with an acquired brain injury. Brain Inj 2005;19:331–335.
   PubMed Web of Science ®Google Scholar
• Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol 2010;17 Suppl 2:57–73.
   PubMed Web of Science ®Google Scholar
• Bayram S, Sivrioglu K, Karli N, Ozcan O. Low-dose botulinum toxin with short-term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am J Phys Med Rehabil 2006;85:75–81.
   PubMed Web of Science ®Google Scholar
• Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am J Phys Med Rehabil 1998;77:510–515.
   PubMed Web of Science ®Google Scholar
• Johnson CA, Burridge JH, Strike PW, Wood DE, Swain ID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil 2004;85:902–909.
   PubMed Web of Science ®Google Scholar
• Hesse S, Krajnik J, Luecke D, Jahnke MT, Gregoric M, Mauritz KH. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 1996;27:455–460.
   PubMed Web of Science ®Google Scholar
• Cioni M, Esquenazi A, Hirai B. Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot. Am J Phys Med Rehabil 2006;85:600–606.
   PubMed Web of Science ®Google Scholar
• Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993;2:221–226.
   PubMed Web of Science ®Google Scholar
• Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 2001;39:1039–1047.
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861–873.
   PubMed Web of Science ®Google Scholar
• Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002;14:109–114.
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Mayer N, Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am J Phys Med Rehabil 2008;87:305–10; quiz 311, 329.
   PubMed Web of Science ®Google Scholar
• Evans MD, Goldie PA, Hill KD. Systematic and random error in repeated measurements of temporal and distance parameters of gait after stroke. Arch Phys Med Rehabil 1997;78:725–729.
   PubMed Web of Science ®Google Scholar
• Arnadottir SA, Mercer VS. Effects of footwear on measurements of balance and gait in women between the ages of 65 and 93 years. Phys Ther 2000;80:17–27.
   PubMed Web of Science ®Google Scholar
• Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142–148.
   PubMed Web of Science ®Google Scholar
• Society AT. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–117.
   PubMed Web of Science ®Google Scholar
• Vos-Vromans DC, de Bie RA, Erdmann PG, van Meeteren NL. The responsiveness of the ten-meter walking test and other measures in patients with hemiparesis in the acute phase. Physiother Theory Pract 2005;21:173–180.
   PubMedGoogle Scholar
• Wade DT, Wood VA, Heller A, Maggs J, Langton Hewer R. Walking after stroke. Measurement and recovery over the first 3 months. Scand J Rehabil Med 1987;19:25–30.
   PubMedGoogle Scholar
• Boyd R, Graham K. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6(Suppl 4):S23–S35.
   Google Scholar
• Guyatt GH, Townsend M, Berman LB, Keller JL. A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis 1987;40:1129–1133.
   PubMedGoogle Scholar
• Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178–S189.
   PubMed Web of Science ®Google Scholar
• Cohen J. A power primer. Psychol Bull 1992;112:155–159.
   PubMed Web of Science ®Google Scholar
• Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420–428.
   PubMed Web of Science ®Google Scholar
• Flansbjer UB, Holmbäck AM, Downham D, Patten C, Lexell J. Reliability of gait performance tests in men and women with hemiparesis after stroke. J Rehabil Med 2005;37:75–82.
   PubMed Web of Science ®Google Scholar
• Decq P, Filipetti P, Cubillos A, Slavov V, Lefaucheur JP, Nguyen JP. Soleus neurotomy for treatment of the spastic equinus foot. Groupe d’Evaluation et de Traitement de la Spasticité et de la Dystonie. Neurosurgery 2000;47:1154–60; discussion 1160.
   PubMed Web of Science ®Google Scholar
• Boyd RN, Pliatsios V, Starr R, Wolfe R, Graham HK. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2000;42:32–41.
   PubMed Web of Science ®Google Scholar
• Wallen MA, O’flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil 2004;85:192–200.
   PubMed Web of Science ®Google Scholar
• Stoquart GG, Detrembleur C, Palumbo S, Deltombe T, Lejeune TM. Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study. Arch Phys Med Rehabil 2008;89:56–61.
   PubMed Web of Science ®Google Scholar
• Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007;21:331–337.
   PubMed Web of Science ®Google Scholar
• Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A single-blinded, randomized pilot study of botulinum toxin type A combined with non-pharmacological treatment for spastic foot. J Rehabil Med 2008;40:870–872.
   PubMed Web of Science ®Google Scholar
• Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37–40.
   PubMed Web of Science ®Google Scholar
• Eleopra R, Tugnoli V, De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 1997;12:89–94.
   PubMed Web of Science ®Google Scholar
• Lagalla G, Danni M, Reiter F, Ceravolo MG, Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000;79:377–84; quiz 391.
   PubMed Web of Science ®Google Scholar
• Thilmann AF, Fellows SJ, Garms E. The mechanism of spastic muscle hypertonus. Variation in reflex gain over the time course of spasticity. Brain 1991;114 (Pt 1A):233–244.
   PubMed Web of Science ®Google Scholar
• Childers MK, Stacy M, Cooke DL, Stonnington HH. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. Am J Phys Med Rehabil 1996;75:462–469.
   PubMed Web of Science ®Google Scholar
• Rousseaux M, Launay MJ, Kozlowski O, Daveluy W. Botulinum toxin injection in patients with hereditary spastic paraparesis. Eur J Neurol 2007;14:206–212.
   PubMed Web of Science ®Google Scholar